Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Anti-Neoplastic Agents Market Growth in 2025?

In recent times, the market size for anti-neoplastic agents has experienced substantial growth. The market value, which is set to rise from $130.01 billion in 2024 to $142.82 billion in 2025, will do so at a compound annual growth rate (CAGR) of 9.9%. The expansion during the historic period can be linked to factors such as a rise in cancer cases, a growing need for therapies, an increased preference for minimally invasive cancer treatments, and the demand for cost-effective anti-neoplastic treatments.

What Is the Forecast for the Anti-Neoplastic Agents Market Size Through 2029?

The market size for anti-neoplastic agents is poised for robust expansion in the coming years, with a projection to reach $202.12 billion in 2029, growing at a compound annual growth rate (CAGR) of 9.1%. The anticipated growth over the forecast timeframe can be attributed to factors such as the increasing knowledge and awareness among patients, government initiatives, the rising trend of individualized cancer treatments, and an enhanced emphasis on quality of life during cancer treatment. Key trends expected during the forecast period are progress in oncology research, the evolution of targeted therapies, innovations in biotechnology, and advances in diagnostic tools.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12901&type=smp

What are the Key Market Players in Anti-Neoplastic Agents Market and How They’re Evolving?

Major companies operating in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.

What Are the Primary Growth Drivers in the Anti-Neoplastic Agents Market?

The growth of the antineoplastic agent market is predicted to be spurred by the escalating number of cancer cases. Cancer, a group of diseases that can occur in virtually any organ or tissue in the human body, arises when irregular cells multiply out of control, exceed their usual limits and either spread to other organs or infiltrate nearby body parts. Antineoplastic agents are crucial to cancer treatment as they stall the growth and division of cancer cells using several mechanisms such as DNA damage, cell cycle interruption, and disruption of vital cellular pathways. For instance, in February 2024, the International Agency for Research on Cancer (IARC), a French-based global agency that encourages international cooperation in cancer research, reported the latest global cancer burden estimates. According to these, the cancer burden is projected to increase to over 35 million in 2050, reflecting a jump of 77% compared to an estimated 20 million in 2022. As a result, the rising frequency of cancer cases is fueling the expansion of the antineoplastic agent market. The anti-neoplastic agent market’s growth is also expected to be spurred by an increase in investment in cancer research. Such investment involves supplying financial resources to aid scientific initiatives focused on studying, preventing, diagnosing, and treating cancer. Enhanced funding for cancer research enables pharmaceutical and biotech companies to push forward in discovering, developing, and thoroughly testing new anti-neoplastic agents. This includes identifying drug targets and creating potential candidates. For instance, the Department of Health and Aged Care, an Australian government entity, invested $893.5 million in March 2022 to augment cancer services and outcomes. This figure incorporated $329.4 million for new cancer drugs like Trodelvy for triple-negative breast cancer, Lynparza for metastatic castration-resistant prostate cancer, and Mylotarg for acute myeloid leukemia, which could benefit hundreds of patients each year. Therefore, increased investment in cancer research is likely to stimulate the growth of the anti-neoplastic agent market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12901&type=smp

What Are the Leading Segments in the Global Anti-Neoplastic Agents Industry?

The anti-neoplastic agents market covered in this report is segmented –

1) By Type: Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous

2) By Disease Type: Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Other Disease Types

3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Alkyl Sulfonates, Nitrosoureas, Triazines

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues, Folate Antagonists

3) By Hormones and Antagonists: Estrogens and Antiestrogens, Androgens and Antiandrogens, Glucocorticoids

4) By Miscellaneous: Vinca Alkaloids, Taxanes, Antibiotic Antineoplastics, Targeted Therapy Agents

What Are the Key Market Trends in the Anti-Neoplastic Agents Industry?

Leading firms in the anti-neoplastic agent industry are concentrated on advancing their clinical procedures to maintain market dominance. For example, in March 2022, Switzerland’s pharmaceutical firm, Novartis AG, publicized the approval of Pluvicto by the Food and Drug Administration (FDA). Pluvicto, a pioneering targeted radioligand therapy, has been developed to treat progressive, Prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC). The treatment involves the administration of 7.4 GBq (200 mCi) of Pluvicto intravenously, every six weeks, capping at six rounds or in cases of disease progression or intolerable toxicity. Patients with mCRPC who have received prior treatment should be considered for Pluvicto therapy, depending on their tumor’s PSMA expression, assessed using Locametz or another FDA-approved PSMA-11 imaging agent.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

What Is the Regional Outlook for the Anti-Neoplastic Agents Market?

North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12901

This Report Delivers Insight On:

1. How big is the anti-neoplastic agents market, and how is it changing globally?

2. Who are the major companies in the anti-neoplastic agents market, and how are they performing?

3. What are the key opportunities and risks in the anti-neoplastic agents market right now?

4. Which products or customer segments are growing the most in the anti-neoplastic agents market?

5. What factors are helping or slowing down the growth of the anti-neoplastic agents market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model